Table 1.
Summary of MI/R injury drugs.
| Target | Target type | Drugs | KEGG pathway | |
|---|---|---|---|---|
| 1 | Angiopoietin 1 receptor (TEK) | Clinical trial target | AKB-9778 (Goel et al., 2013) | Ras signaling pathway; Rap1 signaling pathway; HIF-1 signaling pathway; PI3K-Akt signaling pathway; rheumatoid arthritis |
| 2 | Adenosine A2b receptor (ADORA2B) | Successful target | Adenosine (Xin et al., 2020) | Calcium signaling pathway; Rap1 signaling pathway; neuroactive ligand-receptor interaction; vascular smooth muscle contraction; alcoholism |
| 3 | Adrenergic receptor beta-1 (ADRB1) | Successful target | Metoprolol (Qin et al., 2020) | Calcium signaling pathway; cGMP-PKG signaling pathway; cAMP signaling pathway; neuroactive ligand-receptor interaction; endocytosis; adrenergic signaling in cardiomyocytes; Gap junction; salivary secretion; dilated cardiomyopathy |
| 4 | Dipeptidyl peptidase 4 (DPP-4) | Clinical trial target | REC-01(Jackson, 2017) | Protein digestion and absorption; IL2 signaling pathway; TGF-beta receptor signaling pathway |
| 5 | Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) | Successful target | Abciximab (Eitel et al., 2013) | Platelet degranulation; elastic fiber formation; PECAM1 interactions; molecules associated with elastic fibers; Integrin cell surface interactions; syndecan interactions; ECM proteoglycans; integrin alphaIIb beta3 signaling; p130Cas linkage to MAPK signaling for integrins; VEGFA-VEGFR2 pathway; MAP2K and MAPK activation |
| 6 | Lecithin-cholesterol acyltransferase (LCAT) | Clinical trial target | MEDI6012 (Althaf et al., 2015) | Glycerophospholipid metabolism |
| 7 | Leukotriene A-4 hydrolase (LTA4H) | Successful target | Bestatin (W et al., 2018) | Arachidonic acid metabolism; metabolic pathways |
| 8 | P2Y purinoceptor 12 (P2RY12) | Successful target | Prasugrel; Brilinta(B, 2010) | Platelet activation |
| 9 | Poly [ADP-ribose] polymerase 1 (PARP1) | Successful target | Nicotinamide (EJ et al., 2009) | Base excision repair; NF-kappa B signaling pathway |
| 10 | Protein kinase C delta (PRKCD) | Clinical trial target | KAI-9803 (Gross and Gross, 2007) | Chemokine signaling pathway; vascular smooth muscle contraction; tight junction; Fc epsilon RI signaling pathway; Fc gamma R-mediated phagocytosis; neurotrophin signaling pathway; inflammatory mediator regulation of TRP channels; GnRH signaling pathway; estrogen signaling pathway; Type II diabetes mellitus |
| 11 | Protein kinase C epsilon (PRKCE) | Clinical trial target | Meprobamate(Mochly-Rosen et al., 2012) | cGMP-PKG signaling pathway; sphingolipid signaling pathway; vascular smooth muscle contraction; tight junction; Fc epsilon RI signaling pathway; Fc gamma R-mediated phagocytosis; inflammatory mediator regulation of TRP channels; type II diabetes mellitus; microRNAs in cancer |
| 12 | Proteinase activated receptor 1 (F2R) | Successful target | Vorapaxar (Maki et al., 2010) | Calcium signaling pathway; Rap1 signaling pathway; cAMP signaling pathway; neuroactive ligand-receptor interaction; endocytosis; PI3K-Akt signaling pathway; complement and coagulation cascades; platelet activation; regulation of actin cytoskeleton; pathways in cancer |
| 13 | Sodium/hydrogen exchanger (SLC) | Literature-reported target | FR-183998 (Ishizaki et al., 2008) | cAMP signaling pathway; cardiac muscle contraction; adrenergic signaling in cardiomyocytes; regulation of actin cytoskeleton; thyroid hormone signaling pathway; salivary secretion; gastric acid secretion; pancreatic secretion; bile secretion; proteoglycans in cancer |
| 14 | Sodium/hydrogen exchanger 1 (SLC9A1) | Clinical trial target | Zoniporide hydrochloride (Tracey et al., 2003) | Calcium signaling pathway; cAMP signaling pathway; cardiac muscle contraction; adrenergic signaling in cardiomyocytes; regulation of actin cytoskeleton; thyroid hormone signaling pathway; salivary secretion; gastric acid secretion; pancreatic secretion; bile secretion; proteoglycans in cancer |
| 15 | Thromboxane A2 receptor (TBXA2R) | Successful target | Ridogrel (Xavier et al., 2009) | Calcium signaling pathway; neuroactive ligand-receptor interaction; platelet activation |
| 16 | Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) | Successful target | Flunarizine (Wulff et al., 2019) | Calcium signaling pathway; MAPK signaling pathway; synaptic vesicle cycle; retrograde endocannabinoid signaling; glutamatergic synapse; long-term depression; type II diabetes mellitus; morphine addiction; nicotine addiction |